

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

Alexa Fluor(R) 700 anti-mouse CD3

RRID:AB_493696

Type: Antibody

Proper Citation

BioLegend Cat# 100215, RRID:AB_493696

Antibody Information

URL: http://antibodyregistry.org/AB_493696

Proper Citation: BioLegend Cat# 100215, RRID:AB_493696

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Alexa Fluor(R) 700 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_493696

Vendor: BioLegend

Catalog Number: 100215

Alternative Catalog Numbers: 100216

Record Creation Time: 20250820T002617+0000

Record Last Update: 20250820T081613+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-mouse CD3.

No alerts have been found for Alexa Fluor(R) 700 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bolli E, et al. (2026) CCL3 is produced by aged neutrophils across cancers and promotes tumor growth. *Cancer cell*, 44(3), 624.

Zhang L, et al. (2026) Bcl11a orchestrates multilineage integrity in aging hematopoiesis by regulating multipotent progenitor fate decisions. *Cell reports*, 45(7), 117716.

Feng C, et al. (2026) METTL3/CD98-mediated glutamate efflux in CAFs drives CD8+ T cell exhaustion and impedes neoadjuvant immunochemotherapy. *Cell reports*, 45(2), 116933.

Xu Y, et al. (2026) A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonates. *Immunity*, 59(1), 79.

Green WD, et al. (2025) Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironment. *Immunity*, 58(7), 1725.

Li S, et al. (2025) Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy. *Cancer immunology research*, 13(8), 1284.

González-Domínguez I, et al. (2025) Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models. *Frontiers in immunology*, 16, 1524477.

Yin Y, et al. (2025) Activated T cells degrade extracellular proteins to enhance effector functions. *Cell reports*, 45(1), 116797.

Nyberg WA, et al. (2025) In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. *Immunity*, 58(2), 499.

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102307.

Zhang T, et al. (2025) Humanized mouse model reveals T cell ANXA2 as a potential therapeutic target in ischemic stroke. *iScience*, 28(5), 112302.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. *Cancer cell*.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Rao Y, et al. (2024) The diversity of inhibitory receptor co-expression patterns of exhausted CD8⁺ T cells in oropharyngeal carcinoma. *iScience*, 27(5), 109668.

Poscablo DM, et al. (2024) An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis. *Cell*, 187(12), 3090.

Slamanig S, et al. (2024) Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. *EBioMedicine*, 105, 105185.

Joshi S, et al. (2024) Tim4 enables large peritoneal macrophages to cross-present tumor antigens at early stages of tumorigenesis. *Cell reports*, 43(4), 114096.

Swaminathan S, et al. (2024) LAG-3- and CXCR5-expressing CD4 T cells display progenitor-like properties during chronic visceral leishmaniasis. *Cell reports*, 43(3), 113879.

Lança T, et al. (2022) IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage. *Immunity*, 55(8), 1431.

Di Pilato M, et al. (2021) CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. *Cell*, 184(17), 4512.